RTW Investments LP grew its position in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 0.3% in the second quarter, Holdings Channel reports. The fund owned 13,541,997 shares of the biopharmaceutical company’s stock after acquiring an additional 45,095 shares during the period. Achillion Pharmaceuticals makes up 2.8% of RTW Investments LP’s portfolio, making the stock its 10th largest position. RTW Investments LP owned about 0.10% of Achillion Pharmaceuticals worth $38,324,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. UBS Group AG boosted its position in Achillion Pharmaceuticals by 213.6% during the 1st quarter. UBS Group AG now owns 305,137 shares of the biopharmaceutical company’s stock worth $1,132,000 after acquiring an additional 207,824 shares during the last quarter. Northern Trust Corp boosted its position in Achillion Pharmaceuticals by 9.1% during the 1st quarter. Northern Trust Corp now owns 1,574,153 shares of the biopharmaceutical company’s stock worth $5,840,000 after acquiring an additional 131,219 shares during the last quarter. Acadian Asset Management LLC acquired a new position in Achillion Pharmaceuticals during the 2nd quarter worth approximately $135,000. Opaleye Management Inc. boosted its position in Achillion Pharmaceuticals by 148.9% during the 1st quarter. Opaleye Management Inc. now owns 1,095,100 shares of the biopharmaceutical company’s stock worth $4,063,000 after acquiring an additional 655,100 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its position in Achillion Pharmaceuticals by 49.4% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 650,000 shares of the biopharmaceutical company’s stock worth $2,412,000 after acquiring an additional 215,000 shares during the last quarter. 78.37% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have weighed in on the company. Zacks Investment Research raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 28th. BidaskClub raised Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 1st. ValuEngine raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 1st. Finally, Barclays raised Achillion Pharmaceuticals from an “underweight” rating to an “equal weight” rating and set a $5.00 price target for the company in a research report on Monday, May 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $4.67.

Shares of Achillion Pharmaceuticals stock opened at $3.33 on Friday. Achillion Pharmaceuticals, Inc. has a 12-month low of $2.33 and a 12-month high of $5.00. The company has a market cap of $486.44 million, a PE ratio of -5.37 and a beta of 1.03.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. research analysts forecast that Achillion Pharmaceuticals, Inc. will post -0.52 earnings per share for the current year.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Further Reading: What is the NASDAQ Stock Market?

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.